Locust Walk analyzed the evolving landscape of China’s biotech out-licensing market and its impact on global dealmaking.
Locust Walk’s Overview of AI in Biotech report discusses how AI has profoundly impacted drug discovery and the pharmaceutical industry in the last five years, with AI-derived assets representing nearly half of the preclinical pipeline.
The Deal Makers of Japan series aims to bridge the gap and offer insight to a global biopharma audience to the Japanese pharma industry.
While these key pillars are not exhaustive and approaches may overlap between multiple, these areas have seen a great deal of innovation and attention from strategics and investors as a result.
The CAR-T and oncology cell therapy landscape has broadly seen significant continued development, with over 2,000 therapies in development and ~1,350 active trials globally
Induced pluripotent stem cell (iPSC) technology has the potential to transform the treatment landscape and bring curative options to patients. iPSC-derived cells have the potential to address a wide range of diseases and serve as a fertile ground for new investment opportunities
Locust Walk has conducted an extensive study of mergers and acquisitions in biopharma completed in the past three years and uncovered an interesting trend leaders need to understand
Induced pluripotent stem cell (iPSC) research has encapsulated a global market of scientists, clinicians, and investors and has quickly become the foundation for new regenerative medicines.
The Covid-19 pandemic was the biggest biopharma news of 2020. It may be hard to remember now, but in March of last year, biotech indices had quickly nose-dived, along with the broader market, as the reality of the pandemic became apparent. The prevailing financial sentiment was doom and gloom.
Following up on our recent white paper, Biopharma’s COVID Capital Comeback, here is a look at the greatest risk facing public biopharma companies — single asset failures — and what they can do during this time of robust capital.